Abstract
Silkworm pupae protein is a good source of high quality protein. The hydrolyzates of silkworm pupae protein catalyzed by neutrase, pepsin, acidic protease (Asperqiius usamii NO. 537), flavourzyme, alcalase, and trypsin with inhibitory activity on angiotensin I-converting enzyme (ACE) were identified by HPLC. The hydrolyzates catalyzed by acidic protease exerted the highest inhibitory activity on ACE. The hydrolyzing conditions were optimized by one-factor, factional factorial (FFD), and center composite (CCD) design methods, and response surface methodology (RSM). Statistical analyses showed that regression of the second-order model equation is suitable to describe ACE inhibitory bioactivity. The predicted inhibitory activity of hydrolyzates on ACE was 73.5 % at a concentration of 2.0 mg/ml. Optimized RSM technique decreased IC50 of hydrolyzates inhibiting ACE to 1.4 mg/mL from 2.5mg/ml. The molecular weight of the components of the hydrolyzates with inhibitory activity on ACE varied from less than 500 to about 1000 Da by ultra-filter analysis. These studies suggest that hydrolyzates of silkworm protein contain ACE inhibitory activity that could form a potential source of ACE inhibitor drugs.
Keywords: Angiotensin converting enzyme, silkworm pupae protein, Bombyx mori, hypertension, hydrolyze
Current Pharmaceutical Biotechnology
Title: Hydrolyzates of Silkworm Pupae (Bombyx Mori) Protein is a New Source of Angiotensin I-Converting Enzyme Inhibitory Peptides(ACEIP)
Volume: 9 Issue: 4
Author(s): Wei Wang, Shengrong Shen, Qihe Chen, Bo Tang, Guoqing He, Hui Ruan and Undurti N. Das
Affiliation:
Keywords: Angiotensin converting enzyme, silkworm pupae protein, Bombyx mori, hypertension, hydrolyze
Abstract: Silkworm pupae protein is a good source of high quality protein. The hydrolyzates of silkworm pupae protein catalyzed by neutrase, pepsin, acidic protease (Asperqiius usamii NO. 537), flavourzyme, alcalase, and trypsin with inhibitory activity on angiotensin I-converting enzyme (ACE) were identified by HPLC. The hydrolyzates catalyzed by acidic protease exerted the highest inhibitory activity on ACE. The hydrolyzing conditions were optimized by one-factor, factional factorial (FFD), and center composite (CCD) design methods, and response surface methodology (RSM). Statistical analyses showed that regression of the second-order model equation is suitable to describe ACE inhibitory bioactivity. The predicted inhibitory activity of hydrolyzates on ACE was 73.5 % at a concentration of 2.0 mg/ml. Optimized RSM technique decreased IC50 of hydrolyzates inhibiting ACE to 1.4 mg/mL from 2.5mg/ml. The molecular weight of the components of the hydrolyzates with inhibitory activity on ACE varied from less than 500 to about 1000 Da by ultra-filter analysis. These studies suggest that hydrolyzates of silkworm protein contain ACE inhibitory activity that could form a potential source of ACE inhibitor drugs.
Export Options
About this article
Cite this article as:
Wang Wei, Shen Shengrong, Chen Qihe, Tang Bo, He Guoqing, Ruan Hui and Das N. Undurti, Hydrolyzates of Silkworm Pupae (Bombyx Mori) Protein is a New Source of Angiotensin I-Converting Enzyme Inhibitory Peptides(ACEIP), Current Pharmaceutical Biotechnology 2008; 9(4) . https://dx.doi.org/10.2174/138920108785161578
DOI https://dx.doi.org/10.2174/138920108785161578 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights
Current Respiratory Medicine Reviews Beta-Blocking Agents and Electroconvulsive Therapy
Current Drug Therapy PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Novel Insight into the Inflammatory and Cellular Responses Following Experimental Glaucoma Surgery: A Roadmap for Inhibiting Fibrosis
Current Molecular Medicine Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets New Targets of Therapy in T-Cell Lymphomas
Current Drug Targets GABAB Receptors as Potential Therapeutic Targets
Current Drug Targets - CNS & Neurological Disorders The Possible Adverse Effects of Intramuscular Botulinum Toxin Injections and their Management
Current Drug Safety Molecular Properties Prediction and Synthesis of Novel Pyrazoline Carboxamide Analogs as Antitubercular Agents
Anti-Infective Agents The Quality of Life of Thalassemic Patients: The Role of Endocrine Defect Compensation
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of N-Acetyl-L-Cysteine and Hyaluronic Acid on HBOC-201- Induced Systemic and Cerebral Vasoconstriction in the Rat
Current Drug Discovery Technologies Role of Heme Oxygenase-1 in Vascular Disease
Current Pharmaceutical Design B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target
Current Molecular Medicine Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews Heart Failure Pharmacotherapy: Differences Between Adult and Paediatric Patients
Current Medicinal Chemistry Model Systems for Pulmonary Infectious Diseases: Paradigms of Anthrax and Tuberculosis
Current Topics in Medicinal Chemistry Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Surfactant Replacement Therapy in Pediatric Acute Lung Injury/Acute Respiratory Distress Syndrome
Current Respiratory Medicine Reviews Laparoscopic Surgery for Pheochromocytoma and Paraganglioma Removal: A Retrospective Analysis of Anaesthetic Management
Current Hypertension Reviews Urocortin: Cardiovascular Actions and Therapeutic Implications
Letters in Drug Design & Discovery